Oruka Therapeutics Q2 FY26 net loss widens to $41.2 million; R&D expenses rise to $43.3 million
Reuters2026/08/10 11:06- Oruka posted a Q2 2026 net loss of $41.2 million, widening from $24.6 million a year earlier.
- R&D expenses climbed to $43.3 million from $24.1 million, driven by added trials, a Halozyme upfront payment, higher compensation.
- G&A expenses rose to $6.9 million from $4.3 million, while other income increased to $8.9 million from $3.9 million on higher interest.
- Cash, cash equivalents and marketable securities totaled $1.1 billion as of June 30, 2026, expected to fund operations through a planned ORKA-001 BLA filing.
- EVERLAST-A Week 28 data due end-3Q 2026; EVERLAST-B enrolled 187 with Week 16 data expected in 4Q 2026 to support a Phase 3 start in 1H 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
S&P expects SK Hynix to launch another maximum 40 trillion won buyback in the fourth quarter, coupled with generous dividends, providing new catalysts for Korea's Value-up market trend.
S&P Global Market Intelligence predicts that SK Hynix may announce a new stock buyback plan worth between 20 trillion and 40 trillion Korean won in the fourth quarter of this year. This news pushed its ADR to surge more than 6% on Tuesday, and its Korean stock price once jumped 5% on Wednesday. S&P noted that, alongside Samsung Electronics’ cancellation of treasury stocks and large-scale dividends, these two giants are expected to set a new benchmark for corporate governance in the Korean capital market, helping to resolve the long-standing "Korea discount" dilemma.
Inti Agri Resources’ free float falls to 51.1% in August shareholding report
The higher the yen rises, the more retail investors short! 3.61 trillion yen short bets defy the trend, triggering a short squeeze warning
Even though the yen has reached its highest level in months, Japanese retail investors continue to bet that its sharp rebound will come to an end, and are consistently increasing their short positions.
2-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
